JBH492A
Total Payments
$63,235
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $63,235 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $63,235 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I/IB OPEN-LABEL, MULTI-CENTER DOSE ESCALATION STUDY OF JBH492 IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND NON-HODGKIN'S LYMPHOMA (NHL) | Novartis Pharmaceuticals Corporation | $63,235 | 0 |
Top Doctors Receiving Payments for JBH492A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phoenix, AZ | $63,235 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $63,235
- Total Doctors 0
- Transactions 3
About JBH492A
JBH492A is a drug associated with $63,235 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $63,235 was paid across 3 transactions to 0 doctors.
The most common payment nature for JBH492A is "Unspecified" ($63,235, 100.0% of total).
JBH492A is associated with 1 research study, including "A PHASE I/IB OPEN-LABEL, MULTI-CENTER DOSE ESCALATION STUDY OF JBH492 IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND NON-HODGKIN'S LYMPHOMA (NHL)" ($63,235).